Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.83 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.83 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.83 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.83 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.83 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.83 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.83 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.83 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8400628 | 0.96 | HDAC6 (0.78) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL17010793 | 0.93 | HDAC6 (0.71) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL20220236 | 0.93 | HDAC6 (0.83) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL14700719 | 0.92 | HDAC6 (0.69) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL9950832 | 0.91 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL26319 | 0.91 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL29394147 | 0.91 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL14823504 | 0.91 | HDAC6 (0.73) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL20220234 | 0.91 | HDAC6 (0.86) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL18843 | 0.90 | HDAC6 (0.98) | HDAC6HDAC1HDAC3HDAC4HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2985038-A1 | Lyophilized API preparation | Azad Pharma AG (CH) | 2016-02-17 | — | — | EP | claimed |
| EP-2575785-B1 | ORAL DOSAGE FORMS OF BENDAMUSTINE AND THERAPEUTIC USE THEREOF | PHARMA& SCHWEIZ GMBH (CH) | 2022-10-26 | — | — | EP | disclosed |
| US-11160793-B2 | Solid dosage forms of bendamustine | ASTELLAS DEUTSCHLAND GMBH (DE) | 2021-11-02 | — | — | US | disclosed |
| US-20210275500-A1 | LIQUID BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | HOSPIRA AUSTRALIA PTY LTD (AU) | 2021-09-09 | — | — | US | disclosed |
| US-10993933-B2 | Oral dosage forms of bendamustine | ASTELLAS DEUTSCHLAND GMBH (DE) | 2021-05-04 | — | — | US | disclosed |
| CN-107080742-B | Solid dosage form pharmaceutical composition for oral administration | 安斯泰来德国有限公司 | 2020-08-18 | — | — | CN | disclosed |
| US-10543196-B2 | Oral dosage forms of bendamustine | ASTELLAS DEUTSCHLAND GMBH (DE) | 2020-01-28 | — | — | US | disclosed |
| US-10485787-B2 | Oral dosage forms of bendamustine and therapeutic use thereof | ASTELLAS DEUTSCHLAND GMBH (DE) | 2019-11-26 | — | — | US | disclosed |
| EP-2575784-B1 | ORAL DOSAGE FORMS OF BENDAMUSTINE | ASTELLAS DEUTSCHLAND GMBH (DE) | 2018-08-08 | — | — | EP | disclosed |
| EP-2367538-B1 | SOLID DOSAGE FORMS OF BENDAMUSTINE | ASTELLAS DEUTSCHLAND GMBH (DE) | 2017-08-02 | — | — | EP | disclosed |
| US-20140378518-A1 | LYOPHILIZED FORMULATIONS OF BENDAMUSTINE HYDROCHLORIDE | CHEMI S.P.A. (IT) | 2014-12-25 | — | — | US | disclosed |
| US-20140121383-A1 | PROCESS FOR THE PREPARATION OF BENDAMUSTINE HYDROCHLORIDE | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2014-05-01 | — | — | US | disclosed |
| US-20140121383-A1 | PROCESS FOR THE PREPARATION OF BENDAMUSTINE HYDROCHLORIDE | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2014-05-01 | — | — | US | disclosed |
| US-20140018334-A1 | Oral Dosage Forms of Bendamustine | ASTELLAS DEUTSCHLAND GMBH (DE) | 2014-01-16 | — | — | US | disclosed |
| US-20130310571-A1 | METHODS FOR THE PREPARATION OF BENDAMUSTINE | CEPHALON, INC (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130209558-A1 | Oral Dosage Forms of Bendamustine and Therapeutic Use Thereof | ASTELLAS DEUTSCHLAND GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| EP-2575785-A1 | ORAL DOSAGE FORMS OF BENDAMUSTINE AND THERAPEUTIC USE THEREOF | Astellas Deutschland GmbH (DE) | 2013-04-10 | — | — | EP | disclosed |
| US-20120003305-A1 | Oral Dosage Forms Of Bendamustine | ASTELLAS DEUTSCHLAND GMBH (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20120003309-A1 | Solid Dosage Forms Of Bendamustine | ASTELLAS DEUTSCHLAND GMBH (DE) | 2012-01-05 | — | — | US | disclosed |
| WO-2011103150-A2 | LYOPHILIZED PREPARATIONS OF BENDAMUSTINE | CEPHALON, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003305-A1 | Oral Dosage Forms Of Bendamustine | TAS2R42, TAS2R40, TAS2R45 | HDAC6 1882/4885HDAC1 2640/4885HDAC3 2999/4885 |
| US-20140121383-A1 | PROCESS FOR THE PREPARATION OF BENDAMUSTINE HYDROCHLORIDE | BCDIN3D, BCL9, TMBIM6 | HDAC6 830/4885HDAC1 1233/4885HDAC3 1887/4885 |
| US-20130209558-A1 | Oral Dosage Forms of Bendamustine and Therapeutic Use Thereof | MUC1, MALT1, BCL9 | HDAC6 928/4885HDAC1 724/4885HDAC3 2242/4885 |
| US-20130310571-A1 | METHODS FOR THE PREPARATION OF BENDAMUSTINE | THPO, HBB, FOLR2 | HDAC6 3939/4885HDAC1 4436/4885HDAC3 4717/4885 |
| US-20210275500-A1 | LIQUID BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | JAK2, SLCO4C1, FGFR3 | HDAC6 673/4885HDAC1 2962/4885HDAC3 2873/4885 |
| US-20140018334-A1 | Oral Dosage Forms of Bendamustine | CYP3A5, TAS2R40, CYP3A43 | HDAC6 1673/4885HDAC1 2539/4885HDAC3 2638/4885 |
| US-10485787-B2 | Oral dosage forms of bendamustine and therapeutic use thereof | MCL1, BCL9, BCL9L | HDAC6 672/4885HDAC1 1181/4885HDAC3 1597/4885 |
| US-20140378518-A1 | LYOPHILIZED FORMULATIONS OF BENDAMUSTINE HYDROCHLORIDE | BHMT, FPGS, FOLR2 | HDAC6 290/4885HDAC1 1887/4885HDAC3 3121/4885 |
| US-10543196-B2 | Oral dosage forms of bendamustine | TAS2R42, TAS2R40, TAS2R45 | HDAC6 1882/4885HDAC1 2640/4885HDAC3 2999/4885 |
| US-11160793-B2 | Solid dosage forms of bendamustine | SORD, SI, SELL | HDAC6 110/4885HDAC1 173/4885HDAC3 397/4885 |
| US-20120003309-A1 | Solid Dosage Forms Of Bendamustine | SORD, SI, SELL | HDAC6 122/4885HDAC1 182/4885HDAC3 428/4885 |
| US-10993933-B2 | Oral dosage forms of bendamustine | MCL1, BCL9, BCL9L | HDAC6 620/4885HDAC1 1074/4885HDAC3 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.